Get the Stockscreener App
6.7606
3.09%
-0.1894
Entrada Therapeutics Inc stock is traded at $6.7606, with a volume of 173.47K.
It is down -3.09% in the last 24 hours and up +12.25% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$6.95
Open:
$6.9
24h Volume:
173.47K
Relative Volume:
0.64
Market Cap:
$257.51M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
2.284
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-7.87%
1M Performance:
+12.25%
6M Performance:
-27.03%
1Y Performance:
-61.73%
1-Day Range:
$6.35
$6.94
1-Week Range:
$6.35
$7.535
52-Week Range:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.77 | 264.36M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.29 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.61 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.65 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.17 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
How risky is Entrada Therapeutics Inc. stock nowQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
Will Entrada Therapeutics Inc. stock gain from strong economy2025 Dividend Review & Growth-Oriented Investment Plans - newser.com
Real time pattern detection on Entrada Therapeutics Inc. stockQuarterly Profit Review & Smart Allocation Stock Tips - newser.com
Why Entrada Therapeutics Inc. stock is favored by pension fundsLayoff News & Verified Momentum Stock Alerts - newser.com
How Entrada Therapeutics Inc. stock benefits from strong dollarChart Signals & Reliable Price Action Trade Plans - newser.com
Understanding Entrada Therapeutics Inc.’s price movementPortfolio Risk Summary & AI Powered Market Trend Analysis - newser.com
Does Entrada Therapeutics Inc. stock trade at a discount to peersMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Multi factor analysis applied to Entrada Therapeutics Inc.CEO Change & Daily Entry Point Alerts - newser.com
Visualizing Entrada Therapeutics Inc. stock with heatmapsProfit Target & Risk Controlled Stock Alerts - newser.com
Applying big data sentiment scoring on Entrada Therapeutics Inc.Treasury Yields & Technical Analysis for Trade Confirmation - newser.com
Entrada Therapeutics Inc expected to post a loss of 94 cents a shareEarnings Preview - TradingView
Is Entrada Therapeutics Inc. forming a bottoming baseJuly 2025 Intraday Action & Accurate Trade Setup Notifications - newser.com
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline - TipRanks
Using Python tools to backtest Entrada Therapeutics Inc. strategies2025 Buyback Activity & Expert Verified Stock Movement Alerts - newser.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Tuesday - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analyzing Entrada Therapeutics Inc. with multi timeframe chartsEarnings Risk Report & Reliable Volume Spike Alerts - newser.com
Entrada Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Entrada (Nasdaq: TRDA) to present at Jefferies London and Evercore Miami conferences - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 7% – What’s Next? - Defense World
Applying sector rotation models to Entrada Therapeutics Inc.2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Published on: 2025-10-27 16:51:27 - newser.com
Published on: 2025-10-27 06:13:39 - newser.com
Published on: 2025-10-26 23:31:02 - newser.com
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):